Interclean Shanghai

BioTelemetry acquires remote patient monitoring platform from Centene subsidiary

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

BioTelemetry, the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced it has acquired the On.Demand remote patient monitoring (RPM) and coaching platform, operated by Envolve People Care, Inc., a Centene Corporation subsidiary.

This acquisition adds chronic RPM and coaching solutions to BioTelemetry’s current suite of acute care connected health products and services, focusing specifically on diabetes, hypertension and chronic heart failure.

As part of this acquisition, and under the companies’ strategic partnership agreement, BioTelemetry becomes the exclusive provider of diabetes RPM services to Centene Medicaid members currently utilizing, implementing or engaged to implement the platform in 2020.

In addition to Centene, BioTelemetry will partner externally with payor, provider and employer organizations to improve health outcomes, reduce costs and eliminate waste using On.Demand’s targeted monitoring and coaching interventions.

“We are excited to add On.Demand to our connected health portfolio,” said Joseph H. Capper, President and CEO of BioTelemetry.

“This acquisition uniquely positions BioTelemetry to deliver population health solutions at a time when remote and telehealth options are increasingly important in improving effectiveness across the healthcare continuum. We are delighted to partner with an organization like Centene, which has demonstrated a clear commitment to improving the lives of so many people and communities.”

On.Demand is a mHealth solution that combines real-time monitoring of biometric data with cellular- and web-based technology, proactive and reactive health coaching, population health reporting and customizable interventions. The platform is designed to supplement a physician’s care plan by increasing patient engagement, improving compliance and reducing costs.

It matches people to the clinical expertise and condition management tools they need when they need them, providing intervention and triage that helps bridge the gap between patient visits. In addition, the platform also includes Alexa Skill. On.Demand users are able to schedule coaching appointments, access educational resources, set reminders, and receive real-time assessments and immediate referrals for mental and physical health needs.

BioTelemetry is the pioneer in patient care monitoring, providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects more efficiently, accurately and cost-effectively. Through its connected health solutions, population health management platform and support of some of the largest clinical trials, BioTelemetry is advancing health and improving lives. BioTelemetry’s suite of services and devices expand across cardiac outpatient telemetry, diabetes, hypertension and weight management.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »